Close the acquisition of Arcellx Inc. through the tender offer and second-step merger
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 23 Feb 2026
- Due
- 30 Jun 2026
- Delivered
- 28 Apr 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“is anticipated to close during the second quarter of 2026, subject to the satisfaction or waiver of customary closing conditions”
What we found
Evidence strength A What the grades mean
Gilead completed the Arcellx acquisition via tender offer and second-step merger in April 2026, ahead of the end-of-Q2 deadline.
-
A Gilead Sciences, Inc. 10-Q filed 2026-05-07
“we successfully completed our tender offer for all outstanding shares of Arcellx other than those already owned by Gilead” ✓ confirmed on the page
-
A Gilead Sciences, Inc. 8-K filed 2026-04-28
“Following completion of the offer, Gilead completed the acquisition of Arcellx through a merger of Gilead’s wholly owned subsidiary with and into Arcellx” ✓ confirmed on the page
-
A Gilead Sciences, Inc. 8-K filed 2026-04-28
“As a result of the completion of the merger, Arcellx has become a wholly owned subsidiary of Gilead” ✓ confirmed on the page
Market reaction: the shares moved +1.9% against the S&P 500 over the three sessions around the disclosure (27 Apr 2026 to 30 Apr 2026). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Merger
- Indicative materiality
- Transformational rules
- Action
- Close
- Deliverable
- Acquisition of Arcellx Inc.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to the satisfaction or waiver of customary closing conditions; tender of a majority of Arcellx outstanding shares together with shares owned by Gilead; receipt of regulatory approvals
- Depends on
- Regulatory, Shareholder, Government, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Gilead Sciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-GILD-006066 · Corrections policy